Back to top
more

MEI Pharma (MEIP)

(Delayed Data from NSDQ)

$3.05 USD

3.05
8,066

-0.05 (-1.61%)

Updated Apr 26, 2024 03:44 PM ET

After-Market: $3.08 +0.03 (0.98%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MEIP

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

MEI Pharma, Inc. [MEIP]

Reports for Purchase

Showing records 21 - 40 ( 141 total )

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 21

06/03/2020

Daily Note

Pages: 3

Thinking Beyond 3L FL; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 22

05/14/2020

Daily Note

Pages: 3

ASCO Abstracts Continue to Support MEI’s Pipeline Strength

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 23

05/11/2020

Company Report

Pages: 6

Steady Progress of Pivotal Study With Topline Expected in 1Q21; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 24

04/15/2020

Daily Note

Pages: 3

Kyowa Kirin Deal Points to Accelerated Path to Market

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 25

02/10/2020

Company Report

Pages: 6

With Timeline Intact, Study Protocol Amendment Delivers Safer Dosing Schedule; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 26

11/11/2019

Company Report

Pages: 6

Looking Ahead to Several Data Readouts From Multiple Programs; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 27

10/07/2019

Daily Note

Pages: 4

Thoughts Following R-D Day

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 28

08/29/2019

Company Report

Pages: 6

Progress on Multiple Fronts; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 29

06/24/2019

Daily Note

Pages: 4

ME-401 May Reinstate the Role of PI3K Inhibition in CLL; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 30

06/07/2019

Daily Note

Pages: 4

ASCO Data Update Continues to Support ME-401’s Superior Safety/Efficacy Balance

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 31

05/10/2019

Company Report

Pages: 6

Steady Progress With Multiple Programs Yielding Data; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 32

03/21/2019

Daily Note

Pages: 4

Our Thoughts Following Investor Meetings

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 33

02/08/2019

Company Report

Pages: 6

Thoughts Around Clinical Progress; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 34

12/20/2018

Company Report

Pages: 74

We Like MEI’s Pipeline Strength and Diversity; Initiate With Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 150.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 35

01/22/2018

Industry Report

Pages: 8

Healthcare - Biotech: 2018 Epigenetic Almanac

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 36

02/03/2017

Daily Note

Pages: 4

Dropping Coverage due to Realignment of Analyst Resources

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 37

12/06/2016

Industry Report

Pages: 9

Additional ASH Updates for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 38

08/02/2016

Company Report

Pages: 5

Pracinostat Granted Breakthrough Therapy Designation Ahead of Ph 3, But Study Financing Remains a Question, Reiterate NEUTRAL and $2 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 39

04/15/2016

Company Report

Pages: 7

Ph 3 Pracinostat Study in AML Teed up for 2H16, but Expenses Remain a Concern, Reiterate NEUTRAL and Reducing PT

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 40

12/07/2015

Daily Note

Pages: 6

MEIP to Initiate Ph 3 Registration Study for Pracinostat in Newly Diagnosed Elderly AML

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party